Talking to VnExpress on the morning of June 8, associate professor, Dr. Vu Dinh Thien, Director of the Clinical Trial Center, Central Institute of Hygiene and Epidemiology, said the research team sent a total of 720 serum samples of

Experts in Canada will evaluate the level of antibody production of the first and second doses of Covivac vaccine, as a basis for choosing the appropriate dose level for phase two and three trials.

If these results are satisfactory, the research team will report to the Ministry of Health and request permission for phase two testing on 300 people in Vu Thu district, Thai Binh province.

Phase three is expected to test on 10,000 people.

Covivac is a Covid-19 vaccine researched and developed by the Institute of Vaccines and Medical Biologicals (Ivac), based on chicken egg embryo technology.

The vaccine began phase one clinical testing in March, conducted by Hanoi Medical University in collaboration with the Central Institute of Hygiene and Epidemiology, on 120 volunteers.

The research team completed a two-dose test injection for volunteers in mid-May. The health of 120 people who received the Covivac test injection is currently stable, with no unwanted reactions or late-appearing side effects.

Ivac representatives said they intend to apply for emergency licensing for Covivac immediately after the three testing phases are completed.

Volunteers monitor health after injection at Hanoi Medical University, March. Photo: Giang Huy.